Population approaches in paediatrics

Fundamental and Clinical Pharmacology

Volumn 22, Issue 6, 2008, Pages 575-578

  Chatelut, Etienne ^a  

^a UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Children; Pharmacokinetic pharmacodynamic relationship; Population pharmacokinetics

Indexed keywords

CEFEPIME; FELBAMATE; SOTALOL;

CONFERENCE PAPER; DRUG LEGISLATION; DRUG RESEARCH; HUMAN; PHARMACODYNAMICS; POPULATION RESEARCH; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; HUMANS; INFANT; INFANT, NEWBORN; MODELS, BIOLOGICAL; PEDIATRICS; PHARMACOKINETICS; POPULATION SURVEILLANCE; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 57049124782     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2008.00647.x     Document Type: Conference Paper

References (16)

1. Meibohm B., Laer S., Panetta J.C., Barrett J.S. Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J. (2005) 7 E475 E487.
2. Friis-Hansen B. Water distribution in the foetus and newborn infant. Acta Paediatr. Scand. Suppl. (1983) 305 7 11.
3. Kearns G.L., Reed M.D. Clinical pharmacokinetics in infants and children. A reappraisal. Clin. Pharmacokinet. (1989) 17 (Suppl. 1) 29 67.
4. Kearns G.L., Abdel-Rahman S.M., Alander S.W. et al. Developmental pharmacology - drug disposition, action, and therapy in infants and children. N. Engl. J. Med. (2003) 349 1157 1167.
5. Rane A., Tomson G. Prenatal and neonatal drug metabolism in man. Eur. J. Clin. Pharmacol. (1980) 18 9 15.
6. Blake M.J., Castro L., Leeder J.S., Kearns G.L. Ontogeny of drug metabolizing enzymes in the neonate. Semin. Fetal Neonatal Med. (2005) 10 123 138.
7. Fukudo M., Yano I., Masuda S. et al. Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. Clin. Pharmacol. Ther. (2006) 80 331 345.
8. Tod M., Jullien V., Pons G. Facilitation of drug evaluation in children by population methods and modelling. Clin. Pharmacokinet. (2008) 47 231 243.
9. Capparelli E., Hochwald C., Rasmussen M. et al. Population pharmacokinetics of cefepime in the neonate. Antimicrob. Agents Chemother. (2005) 49 2760 2766.
10. Shi J., Ludden T.M., Melikian A.P., Gastonguay M.R., Hinderling P.H. Population pharmacokinetics and pharmacodynamics of sotalol in pediatric patients with supraventricular or ventricular tachyarrhythmia. J. Pharmacokinet. Pharmacodyn. (2001) 28 555 575.
11. Banfield C.R., Zhu G.R., Jen J.F. et al. The effect of age on the apparent clearance of felbamate: a retrospective analysis using nonlinear mixed-effects modeling. Ther. Drug Monit. (1996) 18 19 29.
12. Krishna R., Krishnaswami S., Kittner B., Sankoh A.J., Jensen B.K. The utility of mixed-effects covariate analysis in rapid selection of doses in pediatric subjects: a case study with fexofenadine hydrochloride. Biopharm. Drug Dispos. (2004) 25 373 387.
13. Pein F., Michon J., Valteau-Couanet D. et al. High-dose melphalan, etoposide, and carboplatin followed by autologous stem-cell rescue in pediatric high-risk recurrent Wilms' tumor: a French Society of Pediatric Oncology study. J. Clin. Oncol. (1998) 16 3295 3301.
14. Rubie H., Doz F., Vassal G. et al. Individual dosing of carboplatin based on drug monitoring in children receiving high-dose chemotherapy. Eur. J. Cancer (2003) 39 1433 1438.
15. Chatelut E., Boddy A.V., Peng B. et al. Population pharmacokinetics of carboplatin in children. Clin. Pharmacol. Ther. (1996) 59 436 443.
16. Urien S. MicroPharm-K, a microcomputer interactive program for the analysis and simulation of pharmacokinetic processes. Pharm. Res. (1995) 12 1225 1230.